Table 1.

Background and baseline characteristics of the study population

	Total						MPHD						Isolated GHD
	n	median	p10	p90	mean	SD	n	median	p10	p90	mean	SD	n	median	p10	p90	mean	SD
Background
Birth weight, SDS	127	–0.55	–2.08	0.95	–0.66	1.21	37	–0.52	–1.96	0.58	–0.58	1.14	90	–0.60	–2.35	1.07	–0.69	1.24
Birth length, SDS	112	–0.88	–2.38	1.04	–0.75	1.27	33	–0.83	–2.35	0.73	–0.69	1.15	79	–0.95	–2.52	1.05	–0.78	1.33
Father height, SDS	127	–1.20	–2.55	–0.11	–1.23	1.13	37	–1.05c	–2.16	0.63	–0.84d	1.06	90	–1.32	–2.68	–0.22	–1.40	1.12
Mother height, SDS	127	–1.11	–2.66	0.24	–1.13	1.21	37	–0.78	–3.34	0.88	–0.92	1.56	90	–1.11	–2.61	0.23	–1.22	1.02
MPH, SDS	127	–1.52	–3.02	–0.07	–1.47	1.16	37	–1.07d	–3.06	0.72	–1.09d	1.41	90	–1.66	–2.77	–0.31	–1.62	1.00
Maximum GH peak, μg/l	127	4.6	1.2	8.6	4.8	2.7	37	2.9b	1.1	6.1	3.2b	1.9	90	5.6	1.8	8.8	5.4	2.7
At the start of GH treatment
Age, years	127	7.0	2.3	11.0	7.1	3.1	37	5.9c	1.7	9.6	5.9c	2.6	90	7.7	2.7	11.2	7.5	3.2
Height, SDS	127	–3.42	–5.11	–2.48	–3.58	1.00	37	–3.75d	–5.75	–2.36	–3.97d	1.34	90	–3.30	–4.55	–2.61	–3.42	0.78
Ht SDS minus MPH SDS	127	–2.36	–4.09	–0.93	–2.39	1.27	37	–2.93b	–5.25	–1.13	–3.08b	1.61	90	–2.22	–3.13	–0.78	–3.08	1.61
Weight, SDS	127	–2.71	–5.09	–1.38	–3.02	1.51	37	–2.91	–6.33	–1.05	–3.32	1.90	90	–2.64	–4.88	–1.44	–2.89	1.31
BMI, SDS	119	–0.28	–1.99	0.87	–0.43	1.09	33	0.07	–1.76	1.25	–0.16	1.15	86	–0.36	–2.00	0.64	–0.53	1.06
GH dose, μg/kg/day	127	27.6	23.6	35.5	28.7	4.8	37	27.9	22.6	38.2	29.4	5.7	90	27.4	23.7	34.9	28.4	4.4
At nFAH
Age, years	127	17.5	15.0	19.2	17.4	1.5	37	17.9d	15.9	19.2	17.8d	1.3	90	17.2	14.8	19.3	17.2	1.6
nFAH all, SDS	127	–1.63	–3.05	–0.16	–1.63	1.06	37	–1.39d	–2.97	0.26	–1.35d	1.22	90	–1.77	–3.08	–0.26	–1.74	0.98
nFAH males, cm	82	169.7	160	178.4	169.5	6.7	27	171.7	161.8	181.7	171.9	7.6	55	169.1	160	175.0	168.3	6.0
nFAH males, SDS	82	–1.63	–3.13	–0.35	–1.70	1.01	27	–1.39	–2.87	0.10	–1.36	1.15	55	–1.77	–3.12	–0.91	–1.87	0.90
nFAH females, cm	45	157	149.4	167	157.8	6.8	10	157.2	152.4	167.7	158.7	8.7	35	157.0	149.6	166.3	157.5	6.3
nFAH females, SDS	45	–1.62	–2.91	0.07	–1.49	1.15	10	–1.58	–2.40	0.19	–1.34	1.46	35	–1.62	–2.86	–0.03	–1.53	1.07
Total ΔHt SDSa	127	1.79	0.83	3.45	1.96	1.24	37	2.26b	1.13	4.73	2.62b	1.41	90	1.59	0.59	2.92	1.69	1.06
nFAH SDS minus MPH SDS	127	–0.37	–1.70	0.69	–0.43	0.97	37	–0.42	–1.89	1.06	–0.46	1.08	90	–0.35	–1.53	0.68	–0.42	0.93
BMI, SDS	119	–0.09	–1.89	1.32	–0.23	1.27	37	–0.06	–1.67	1.42	–0.13	1.31	82	–0.10	–1.94	1.27	–0.27	1.25
Duration of GH therapy, years	127	9.6	5.3	13.7	9.6	3.1	37	10.9c	7.3	15.4	10.9c	2.8	90	8.8	5.0	13.6	9.0	3.1
Duration of GH therapy before puberty, years	125	5.2	1.9	9.4	5.4	2.9	37	6.7c	2.7	10.9	6.6c	2.8	88	4.4	1.5	8.6	4.8	2.8

MPHD = Multiple pituitary hormone deficiency; GHD = growth hormone deficiency; MPH = midparental height; GH = growth hormone; BMI = body mass index; nFAH = near-final adult height. The reference by Roelants et al. [9] was used for the SDS calculations except for birth weight and birth length SDS for which Niklasson et al. [8] was used.

^aGain in Ht SDS from the start of GH treatment until nFAH.

^bp < 0.001

^cp < 0.01

^dp < 0.05 for comparison between MPHD and isolated GHD.